CJC-1295 Peptide Calculator

CJC-1295 is a tetrasubstituted 29-amino acid synthetic analog of growth hormone-releasing hormone (GHRH), engineered for dramatically extended plasma half-life compared to native GHRH(1-29). Native GHRH is cleaved within minutes in vivo by dipeptidyl peptidase IV (DPP-IV) at the Ala²-Asp³ bond; CJC-1295 circumvents this through four amino acid substitutions (Ala²→Aib, Gln⁸→Ala, Ala¹⁵→Ala, Asn²⁷→Asp, Arg²⁹→Lys) that collectively confer DPP-IV resistance and enhanced GHRH receptor affinity.

CJC-1295 exists in two pharmacologically distinct research forms that are frequently confused but behave very differently in experimental settings. Understanding the distinction is foundational to designing valid GH-axis research protocols.

CJC-1295 With DAC (Drug Affinity Complex)

The DAC form incorporates a maleimidoproprionic acid (MPA) bioconjugation moiety appended to the C-terminal lysine residue. Upon injection, this reactive maleimide group forms an irreversible thioether covalent bond with the free cysteine-34 residue of circulating serum albumin—a process termed 'bioconjugation in vivo.' Albumin binding provides three pharmacokinetic benefits: protection from enzymatic degradation, reduced renal glomerular filtration (albumin is too large to be cleared), and a depot-like sustained release effect. The result is a terminal elimination half-life of 6–8 days, enabling once-weekly or twice-monthly dosing intervals in research protocols.

The pharmacodynamic consequence of DAC-mediated half-life extension is a sustained, tonic elevation of basal GH and IGF-1 levels rather than discrete pulsatile release. This 'GH bleed' pattern differs fundamentally from endogenous GH physiology and is an important experimental variable when interpreting downstream metabolic and anabolic readouts.

CJC-1295 No DAC (Mod GRF 1-29)

The No DAC form—also called Modified GRF 1-29 (Mod GRF 1-29) in research literature—retains the same four amino acid substitutions for DPP-IV resistance but lacks the albumin-binding MPA moiety. Without bioconjugation, the peptide is cleared via normal renal filtration and endogenous protease activity, yielding a half-life of approximately 30 minutes. This shorter window produces a discrete, physiologically pulsatile GH release pattern when timed to coincide with endogenous GH troughs.

For research protocols modeling physiological GH pulsatility—such as sleep-associated GH secretion studies or GH secretagogue synergy experiments—Mod GRF 1-29 is the appropriate form. Its short action window requires precise administration timing relative to the subject's endogenous ultradian GH rhythm.

GHRH Receptor Agonism and Somatotroph Stimulation

CJC-1295 acts as a potent GHRH receptor agonist at the somatotroph cells of the anterior pituitary gland. GHRH receptors (GHRHR) are class B GPCRs that, upon agonist binding, couple to Gαs proteins and activate adenylyl cyclase, raising intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). CREB activation drives transcription of the GH1 gene and stimulates synthesis and secretion of growth hormone from somatotroph secretory granules.

GH Pulse Amplitude

CJC-1295's primary pharmacodynamic effect is amplification of GH pulse amplitude—the peak concentration of GH released during each secretory event—rather than increasing the frequency of GH pulses. In rodent studies using pulsatile GH modeling, GHRH analogs consistently increase the height of GH peaks while leaving pulse frequency relatively unchanged. This amplitude-centric mechanism is why CJC-1295 is pharmacologically complementary to GH secretagogues (GHRPs) such as Ipamorelin, which act through an independent receptor (GHS-R1a) to primarily modulate pulse frequency.

The GH Axis Feedback Loop

GH secretion is under dual hypothalamic control: GHRH (stimulatory) and somatostatin (inhibitory). CJC-1295 operates within this feedback network—its stimulatory effect on GH release is blunted during periods of high somatostatin tone, which occurs physiologically in the post-meal state and during stress. Consequently, GH response to CJC-1295 administration is most pronounced during somatostatin troughs (fasted, resting states), an important timing consideration for reproducible experimental conditions. The resulting GH elevation drives hepatic IGF-1 synthesis, which via negative feedback suppresses further GHRH secretion and GH release—limiting the runaway stimulation risk inherent in exogenous GHRH agonism.

Vial Sizes and pH Sensitivity

Research-grade CJC-1295 is commonly supplied in 2mg and 5mg lyophilized vials. CJC-1295 is sensitive to pH: stability is optimal between pH 4.5–6.5, which falls within the pH range of standard bacteriostatic water (0.9% benzyl alcohol, pH typically 4.5–7.0). Do not reconstitute with sterile water for injection that has been buffered to near-neutral pH without verifying peptide stability, and avoid reconstitution with acidic vehicles below pH 4.0 that can promote aspartate residue hydrolysis at the Asp³ position.

Step-by-Step Reconstitution Math

The CJC-1295 calculator uses the following formula to determine concentration and draw volume:

• 2mg vial + 2ml BAC water: 10 mcg/unit → 100mcg = 10 units
• 2mg vial + 1ml BAC water: 20 mcg/unit → 100mcg = 5 units
• 5mg vial + 2ml BAC water: 25 mcg/unit → 100mcg = 4 units
• 5mg vial + 5ml BAC water: 10 mcg/unit → 100mcg = 10 units
• Use the CJC-1295 calculator above to verify units for any vial size, BAC water volume, or target dose combination.

Handling Considerations for the DAC Moiety

The maleimide group in the DAC form is reactive by design—it must remain available to bind albumin in vivo. This same reactivity makes it susceptible to thiol-containing solvents (e.g., solutions containing cysteine or glutathione) and to competing nucleophiles. Always use fresh bacteriostatic water as the reconstitution solvent; do not use multi-use BAC water vials that have been opened for extended periods as trace contamination from other compounds can quench the maleimide. Reconstitute gently by injecting BAC water along the inner vial wall and rolling—never shaking—to avoid aggregation of the lipophilic DAC moiety.

The combination of a GHRH analog (CJC-1295) with a GHRP/GHS (Ipamorelin) represents one of the most studied combinatorial peptide protocols in preclinical GH-axis research. The synergy is mechanistically grounded in complementary receptor systems operating on different axes of GH secretory regulation.

Amplitude vs. Frequency: Complementary Mechanisms

CJC-1295 (acting via GHRHR on somatotrophs) primarily increases GH pulse amplitude—it loads the somatotroph with a heightened secretory drive, potentiating the size of each GH release event. Ipamorelin (acting via GHS-R1a) primarily increases the number of GH pulses by suppressing somatostatin tone and directly triggering somatotroph discharge. When co-administered, the two compounds synergize along orthogonal axes: amplitude × frequency = total GH output. Rodent studies combining GHRH analogs with GHRPs have demonstrated GH area-under-the-curve (AUC) values 2–10× greater than either compound alone at equivalent doses, depending on timing and dose.

Receptor Independence as the Mechanistic Basis for Synergy

The GHR receptor (GHS-R1a) and the GHRH receptor are entirely separate GPCRs with non-overlapping intracellular signaling adaptors. GHS-R1a signals via Gαq/11 (phospholipase C, IP3, calcium mobilization), while GHRHR signals via Gαs (adenylyl cyclase, cAMP, PKA). Because both second-messenger cascades converge independently on the same exocytotic machinery in somatotrophs, co-activation produces additive-to-synergistic secretory output without competitive receptor interference—a pharmacologically elegant combination that is difficult to achieve with compounds sharing the same receptor target.

CJC-1295 stability varies meaningfully between the DAC and No DAC forms due to the reactive maleimide group in the former. Both forms require consistent cold-chain management, but the DAC moiety introduces additional degradation pathways.

• Lyophilized at room temperature (20–25°C): Acceptable for short-term transport (<72 hours). Both DAC and No DAC forms show acceptable stability at room temperature as lyophilized powder for up to 2–4 weeks if protected from humidity and light. Not recommended for extended ambient storage.
• Lyophilized at −20°C (long-term): Optimal. Both forms are stable for up to 24 months. Desiccate and seal vials before returning to freezer after each use to prevent moisture ingress.
• Reconstituted at 2°C–8°C: Required. Use within 28 days. The reconstituted DAC form is particularly sensitive to temperature excursions—the maleimide group can undergo hydrolysis to a non-reactive maleamic acid above 25°C, inactivating the albumin-binding mechanism.
• Never freeze reconstituted solution: Ice crystal formation causes mechanical peptide damage and, for the DAC form, can disrupt the maleimide's reactive geometry, reducing in vivo albumin-binding efficiency.
• Light protection: Both forms are moderately UV-sensitive. Store in amber vials or foil-wrapped vials. The maleimide group undergoes photolytic ring-opening under UV exposure, destroying albumin-binding capacity in the DAC form.

Can CJC-1295 and Ipamorelin be mixed in the same syringe for research?

Yes—combining CJC-1295 (particularly the No DAC / Mod GRF 1-29 form) and Ipamorelin in the same syringe immediately before administration is a standard practice in preclinical co-administration protocols and is physicochemically acceptable. Both peptides are stable in BAC water at refrigerated temperatures and there are no documented incompatibilities or co-precipitation events between them in published preclinical literature. The key operational rule is 'draw and use immediately': the combined solution should not be pre-mixed and stored, as the combined formulation's stability has not been formally characterized over time. For the DAC form, the same logic applies—draw from both vials into a single syringe just before the experimental time point, and do not pre-mix vials. The benefit of same-syringe co-administration in research is the precise temporal co-delivery that maximizes synergistic GH release.

Which version is better for steady-state GH levels in research?

For steady-state IGF-1 elevation and sustained GH axis stimulation studies—analogous to protocols investigating long-term metabolic, anabolic, or bone-density effects—CJC-1295 with DAC is the appropriate selection. Its 6–8 day half-life produces a sustained GH 'bleed' that maintains elevated IGF-1 levels with once-weekly dosing, creating a pharmacokinetically stable baseline for multi-week studies. For research investigating GH pulse dynamics, secretory kinetics, or the physiological consequences of pulsatile GH release—including episodic IGF-1 bursts, liver GH receptor pulsatility, or sleep-stage GH coupling—CJC-1295 No DAC (Mod GRF 1-29) is the correct tool. Its 30-minute half-life allows researchers to time discrete, measurable GH secretory events and return subjects to baseline between sampling points, enabling clean pharmacokinetic modeling that is impossible with the DAC form's sustained release profile.